BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...to treat rare diseases, hired Steve Hughes as chief development officer. He was CMO of Organovo...
BioCentury | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

...Viscient seeking merger with Organovo 3D tissue developer Viscient Biosciences Inc. proposed to merge with Organovo...
...company said a combination with Organovo would afford it opportunities in other indications. Viscient said Organovo's...
...shareholders could hold up to 43% of the combined entity. Viscient CEO Keith Murphy was Organovo's...
BioCentury | May 30, 2019
Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

..."FDA Approves Astellas' Xospata in FLT-3 Positive AML" ). Organovo shares surge following bioprinting collaboration Organovo...
...of 3D bioprinted stem cell-based therapeutic tissues to treatment applications for end-stage renal disease (ESKD). Organovo...
...KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance Biotherapeutics Inc. Organovo...
BioCentury | Aug 1, 2018
Company News

Management tracks: Hologic, Tricidia

...David Price as CFO. He was CFO at Concordia International Corp. (TSX:CXR; NASDAQ:CXRX). Bioprinting company Organovo...
BioCentury | Jan 4, 2018
Company News

Management tracks: Acceleron, Selecta

...aTyr Pharma Inc. (NASDAQ:LIFE). David was chief strategy officer and EVP of preclinical development at Organovo...
BioCentury | Apr 12, 2017
Company News

Management tracks

...Bioprinting company Organovo Holdings Inc. (NASDAQ:ONVO) said CEO Keith Murphy will resign, effective April 21. Taylor...
BioCentury | Jan 6, 2017
Finance

Good riddance

...$5.0 $25.2 $29.1 15% Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (A) 10/26/16 $5.2 NA $18.4 NA Organovo...
BioCentury | Oct 24, 2016
Financial News

Organovo Holdings completes follow-on

Organovo Holdings Inc. (NYSE-M:ONVO), San Diego, Calif. Business: Gene/Cell therapy, Supply/Service Date completed: 2016-10-20 Type: Follow-on Raised: $24.8 million Shares: 9 million Price: $2.75 Shares after offering: 101.7 million Underwriters: Jefferies; Evercore; Raymond James; BTIG...
BioCentury | Aug 8, 2016
Company News

Management tracks

...Wapnick as CFO. She was VP of finance at Amgen Inc. (NASDAQ:AMGN). Tissue modeling company Organovo...
BioCentury | Jan 20, 2016
Company News

Management tracks

...Louis O'Dea CMO. O'Dea was CMO at Oxford Immunotec Global plc (NASDAQ:OXFD). Cell therapy play Organovo...
Items per page:
1 - 10 of 36
BioCentury | Jan 8, 2020
Company News

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

...to treat rare diseases, hired Steve Hughes as chief development officer. He was CMO of Organovo...
BioCentury | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

...Viscient seeking merger with Organovo 3D tissue developer Viscient Biosciences Inc. proposed to merge with Organovo...
...company said a combination with Organovo would afford it opportunities in other indications. Viscient said Organovo's...
...shareholders could hold up to 43% of the combined entity. Viscient CEO Keith Murphy was Organovo's...
BioCentury | May 30, 2019
Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

..."FDA Approves Astellas' Xospata in FLT-3 Positive AML" ). Organovo shares surge following bioprinting collaboration Organovo...
...of 3D bioprinted stem cell-based therapeutic tissues to treatment applications for end-stage renal disease (ESKD). Organovo...
...KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance Biotherapeutics Inc. Organovo...
BioCentury | Aug 1, 2018
Company News

Management tracks: Hologic, Tricidia

...David Price as CFO. He was CFO at Concordia International Corp. (TSX:CXR; NASDAQ:CXRX). Bioprinting company Organovo...
BioCentury | Jan 4, 2018
Company News

Management tracks: Acceleron, Selecta

...aTyr Pharma Inc. (NASDAQ:LIFE). David was chief strategy officer and EVP of preclinical development at Organovo...
BioCentury | Apr 12, 2017
Company News

Management tracks

...Bioprinting company Organovo Holdings Inc. (NASDAQ:ONVO) said CEO Keith Murphy will resign, effective April 21. Taylor...
BioCentury | Jan 6, 2017
Finance

Good riddance

...$5.0 $25.2 $29.1 15% Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (A) 10/26/16 $5.2 NA $18.4 NA Organovo...
BioCentury | Oct 24, 2016
Financial News

Organovo Holdings completes follow-on

Organovo Holdings Inc. (NYSE-M:ONVO), San Diego, Calif. Business: Gene/Cell therapy, Supply/Service Date completed: 2016-10-20 Type: Follow-on Raised: $24.8 million Shares: 9 million Price: $2.75 Shares after offering: 101.7 million Underwriters: Jefferies; Evercore; Raymond James; BTIG...
BioCentury | Aug 8, 2016
Company News

Management tracks

...Wapnick as CFO. She was VP of finance at Amgen Inc. (NASDAQ:AMGN). Tissue modeling company Organovo...
BioCentury | Jan 20, 2016
Company News

Management tracks

...Louis O'Dea CMO. O'Dea was CMO at Oxford Immunotec Global plc (NASDAQ:OXFD). Cell therapy play Organovo...
Items per page:
1 - 10 of 36